e-learning
resources
ERJ
2006
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study
Hughes R. J., Jais X., Bonderman D., Suntharalingam J., Humbert M., Lang I., Simonneau G., Pepke-Zaba J.
Source:
Eur Respir J 2006; 28: 138-143
Journal Issue:
July
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hughes R. J., Jais X., Bonderman D., Suntharalingam J., Humbert M., Lang I., Simonneau G., Pepke-Zaba J.. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006; 28: 138-143
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2007; 30: 922-927
Year: 2007
Bosentan for inoperable chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 399s
Year: 2006
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 272s
Year: 2005
Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension
Source: Eur Respir Rev 2009; 19: 64-67
Year: 2010
Open label study of bosentan in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 706s
Year: 2004
Bosentan improves 6-minutes-walk-test in patients with inoperable chronic thrombo-embolic pulmonary hypertension (iCTEPH)
Source: Eur Respir J 2005; 26: Suppl. 49, 272s
Year: 2005
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2004; 23: 595-600
Year: 2004
Longterm survival of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2008 - Acute and chronic pulmonary thromboembolic disease
Year: 2008
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
Source: Eur Respir J 2010; 36: 792-799
Year: 2010
Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020
Year: 2020
Vasodilator treatment in chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension
Year: 2003
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)
Source: Eur Respir J 2015; 45: 1293-1302
Year: 2015
ERS statement on chronic thromboembolic pulmonary hypertension
Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension
Year: 2021
Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension
Source: Eur Respir Rev 2015; 24: 272-282
Year: 2015
Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry
Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension
Year: 2018
Chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2007 - Update on venous thromboembolism
Year: 2007
Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH)
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease
Year: 2008
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 92-98
Year: 2009
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept